Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous Non-Small Cell Lung Cancer

Next Previous
Trial Profile

A Phase II Trial of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Cisplatin; Docetaxel; Erlotinib; Gemcitabine; Paclitaxel; Pemetrexed; Vinorelbine
  • Indications Cancer metastases; Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms PASSPORT
  • Sponsors Genentech

Most Recent Events

  • 01 Sep 2009 Actual patient number (115) added as reported by ClinicalTrials.gov.
  • 01 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 11 Nov 2008 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top